GLP-1 Drugs in Early Pregnancy Linked to Healthier Gestational Weight Gain
A new retrospective study finds GLP-1 use in early pregnancy reduces odds of gaining too little weight, but fetal safety questions remain.
Summary
A retrospective cohort study presented at the American College of Obstetricians and Gynecologists annual meeting examined how GLP-1 receptor agonist drugs — like semaglutide — affect weight gain during pregnancy. Women who used GLP-1 drugs for weight management in early pregnancy were significantly less likely to gain below the recommended amount of weight. Pre-pregnancy use alone did not significantly affect gestational weight gain, possibly because weight tends to rebound after stopping these medications. The study found no significant link between GLP-1 exposure and hypertensive disorders of pregnancy. However, researchers flagged a non-significant signal for increased fetal death risk in the weight-management group, warranting further investigation. Experts stress that evidence in this area remains extremely limited despite rapidly growing use among reproductive-age women.
Detailed Summary
As GLP-1 receptor agonists like semaglutide and tirzepatide surge in popularity for weight management, a critical question is emerging: what happens when women use these drugs around the time of pregnancy? A new retrospective cohort study presented at the 2026 ACOG annual meeting offers some early — though limited — answers.
The central finding is that women who used GLP-1 drugs for weight management during early pregnancy were significantly less likely to gain below the Institute of Medicine's recommended gestational weight levels (adjusted OR 0.29). This suggests the drugs may help prevent insufficient weight gain, which carries its own maternal and fetal risks. Pre-pregnancy-only exposure did not significantly affect weight gain outcomes, possibly reflecting the well-documented rebound weight gain that occurs after GLP-1 discontinuation.
On the safety front, the study found no statistically significant association between GLP-1 exposure and hypertensive disorders of pregnancy in either the diabetes or weight-management cohorts. This is a modest reassurance, though experts note the biological plausibility of a protective effect deserves further study given the non-significant trend toward risk reduction observed.
A notable concern is a signal — though not statistically significant — for higher fetal death rates in the weight-management group (2.9% vs 0.5%). Animal studies have raised similar flags, though human observational data has not confirmed elevated risk. The small sample size limits interpretation, and this finding should not be dismissed.
The broader takeaway is that millions of reproductive-age women are now using GLP-1 drugs, yet the evidence base for safety and efficacy around pregnancy remains extremely thin. Clinicians currently recommend discontinuing these medications during pregnancy, but the downstream effects of stopping — including weight rebound — may carry their own risks. Larger, prospective studies are urgently needed to guide evidence-based clinical guidance.
Key Findings
- GLP-1 use in early pregnancy significantly reduced odds of gaining below recommended gestational weight (aOR 0.29).
- Pre-pregnancy GLP-1 exposure alone did not significantly affect gestational weight gain outcomes.
- No significant association found between GLP-1 exposure and hypertensive disorders of pregnancy.
- A non-significant signal for higher fetal death risk (2.9% vs 0.5%) was observed in the weight-management cohort.
- Evidence on GLP-1 safety around pregnancy remains extremely limited despite rapidly growing use.
Methodology
This is a meeting coverage news report summarizing a retrospective cohort study presented at the 2026 ACOG annual meeting by a Duke University Medical Center resident. The study is observational and retrospective, limiting causal inference. Full peer-reviewed publication and sample size details were not provided in the article.
Study Limitations
The study is retrospective and observational, preventing causal conclusions. Sample sizes appear small, limiting statistical power — particularly for the fetal death signal. Full methodology, confounders controlled, and peer-review status are not available from this meeting abstract coverage alone.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.